Patent application number | Description | Published |
20080213794 | SCREENING FOR GESTATIONAL DISORDERS - The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy. | 09-04-2008 |
20090004669 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia. | 01-01-2009 |
20090117588 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject. | 05-07-2009 |
20090170767 | Soluble Endoglin Compounds for the Treatment and Prevention of Cancer - Disclosed herein are soluble endoglin compounds and kits, pharmaceutical compositions, and articles of manufacture containing soluble endoglin compounds. Also disclosed herein are methods for treating an angiogenesis disorder, such as cancer, using soluble endoglin compounds, provided alone or in combination with a chemotherapeutic agent, an angiogenesis inhibitor, or an antiproliferative compound. | 07-02-2009 |
20090305963 | Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis - The invention features methods and compositions for treating and preventing cancer metastasis, angiogenic disorders, and fibrotic disorders using lipocalin 2 compounds. | 12-10-2009 |
20100221243 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE - Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed. | 09-02-2010 |
20110014197 | METHODS OF TREATING PRE-ECLAMPSIA OR ECLAMPSIA - Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia. | 01-20-2011 |
20110243956 | METHODS OF DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY - Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity. | 10-06-2011 |
20110280825 | EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLICATIONS OF PREGNANCY - The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. | 11-17-2011 |
20120020974 | OPTIMIZING ERYTHROPOIETIN THERAPY - The methods described herein can be used to identify ex ante which hemodialysis patients are likely to develop EPO resistance and therefore will require additional rHu EPO, and to provide treatments that can reduce the need for additional rHu EPO. In addition, the methods can be used to predict which subjects have a higher risk of mortality, to identify high-risk patients who can then be monitored more closely or treated more aggressively. Also provided are kits for carrying out the described methods. | 01-26-2012 |
20130252821 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE - Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed. | 09-26-2013 |
20130324505 | ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY - Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency. | 12-05-2013 |
20140113885 | ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY - Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency. | 04-24-2014 |